Early disturbances in axonal transport, before the onset of Background: gross neuropathology, occur in a spectrum of neurodegenerative diseases including Alzheimer's disease. Kinesin superfamily motor proteins (KIFs) are responsible for anterograde protein transport within the axon of various cellular cargoes, including synaptic and structural proteins. Dysregulated KIF expression has been associated with AD pathology and genetic polymorphisms within kinesin-light chain-1 (KLC1) have been linked to AD susceptibility. We examined the expression of KLC1 in AD, in relation to that of the KLC1 motor complex (KIF5A) and to susceptibility genotypes.
Introduction
Over 90% of Alzheimer's disease (AD) cases are sporadic rather than attributable to a single gene mutation. In these cases, as for many other sporadic adult-onset neurodegenerative diseases, the pathological changes are likely to be caused by a combination of environmental and genetic factors that activate variably independent pathogenic pathways that increase neuronal vulnerability to damage and death 1 . One major genetic risk factor for sporadic disease is the ε4 allele of APOE 2 . Aside from APOE, genome-wide association studies (GWAS), have linked single nucleotide polymorphisms (SNPs) in over 20 genetic loci to AD susceptibility 3 .
A common theme across neurodegenerative diseases is alterations in neuronal connectivity that can give rise to clinical symptoms before neuronal loss 4, 5 . Targeting the processes responsible for the changes in neuronal connectivity is a key therapeutic aim, before consequential axonal loss and neuronal death cause irreversible disability in patients with neurodegenerative disease 6, 7 . A crucial step in this transition from potentially reversible to irreversible disease is the disruption in axonal delivery of membrane-bound organelles from the neuronal soma to the synapse. The development of such disruption has been recognised pathologically in brain tissue, including in AD 8 , by the formation of axonal swellings at an early stage in the disease process.
Kinesin superfamily motor proteins (KIFs) are responsible for most anterograde protein transport within the axon of various cellular cargoes, including synaptic and structural proteins 9 . There are at least 38 different neuronally-enriched KIFs which contain a conserved microtubule-binding domain and a motor domain at their amino (NH 2 -) terminus, which hydrolyses ATP in order to generate motile forces to shift associated cargoes along the axon, via microtubule tracks 10 . The heterogeneous tail (COOH-terminal) domain of KIFs determines their cargobinding specificity 11 .
Early disturbances in axonal transport are a feature of several neurodegenerative diseases [12] [13] [14] , and studies have linked KIF dysregulation to AD 15, 16 . Conventional kinesin member KIF5A transports several cargoes, including APP and β-and γ-secretases, by complexing with kinesin light chain-1 (KLC1). Some have demonstrated APP and β-and γ-secretases are among those transported but other studies have not replicated these findings [17] [18] [19] [20] . Deletion of the KLC1 subunit in mice leads to early selective axonal transport defects, resulting in a disorganised neuronal cytoskeleton with APP, neurofilament (NF) and hyperphosphorylated tau accumulation 21 . Mice transgenic for human APP with mutations that cause familial AD develop abnormal axonal swellings positive for KLC1 and structural axonal component phosphorylated NF-H, long before AD pathology can be detected 8, 22 .
Single nucleotide polymorphisms (SNPs) in the region of the KLC1 gene have been linked to AD susceptibility; in particular, rs8702 has been shown to predict conversion of mild cognitive impairment (MCI) to AD 16, 23, 24 . Our previous studies have shown that SNPs within the KIF5A gene locus, linked to multiple sclerosis (MS) susceptibility, influence KIF5A expression in post-mortem brain 25, 26 .
We and others have found KIF5A expression to be increased in post-mortem AD and PD tissue 27, 28 . KIF members show a degree of functional redundancy, such that more than one KIF may transport a specific cargo 29 . We therefore suggested that KIF5A might be upregulated in AD as compensatory protective response to defects in other, interoperable, axonal transport proteins, facilitating the transport and clearance of aggregating cargoes in the cell body and axon. In support of this hypothesis, we showed that KIF5A levels in both MS and AD correlated inversely with the amount of cargo APP 26, 27 . KIF5A shares many cargoes with anterograde motor protein KIF1B, such as mitochondria and synaptic vesicle proteins, and it can transport cargoes without complexing to KLC1 9, 30 .
In this study we aimed to determine whether KLC1 levels are altered in AD, the relationship between the levels of KLC1 and KIF5A, and whether expression of KLC1 in the cerebral cortex is influenced by KLC1 polymorphisms, which have been linked to AD susceptibility.
Methods

Study cohort
Samples of midfrontal cortex (Brodmann area 8; 500mg) were obtained from the South West Dementia Brain Bank (Bristol, UK), under the terms of South West -Central Bristol Research Ethics Committee approval no 08/H0106/28+5. Our previous studies indicated an influence of post-mortem delay (PMD) on mRNA and protein expression in brain tissue 27 . Therefore, cases with a PMD >72 h were excluded from analysis. We studied 47 cases of AD (in which, AD neuropathological change was an adequate explanation of dementia, according to National Institute on Aging-Alzheimer's Association guidelines 31 ), and 39 age-matched controls with no history of cognitive impairment (Table 1) .
RNA and protein extraction
Both RNA and protein were extracted from each sample by use of the Paris™ Kit (ThermoFisher Scientific; AM1921), according to the manufacturer's instructions. Samples were weighed, divided into 2x 50 mg portions and placed in 2 ml homogenisation tubes, pre-filled with 5x 2.3 mm silica beads (Stratech Scientific; 11079125z-BSP) and 300 µL of Paris™ kit lysis buffer, with the addition of Halt™ Protease and phosphatase inhibitor cocktail and 0.5M EDTA (1:100)
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The discussion and conclusions of the manuscript have been amended to be less speculative and a better reflection of the data presented. (ThermoFisher Scientific; 78440). Samples were homogenised using a Precellys®24 automated homogeniser (Stretton Scientific). Samples were subsequently centrifuged (Sorvall ST 16R) at 10,000 xg for 2 min at 4°C and the soluble protein supernatant removed and stored at -80°C until required. The remaining homogenate was taken through the additional manufacturer's steps for extraction and elution of RNA, before storage at -80°C.
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gDNA extraction
An approximately, 2 mm slice was taken from each brain sample and gDNA extracted using the TaqMan® Sample-to-SNP™ Kit (ThermoFisher Scientific; 4403313). Cortex was placed in lysis buffer, briefly centrifuged and incubated for 3 min at 95°C, before addition of DNA stabilising solution. Samples were then stored at -20°C until use.
Complementary DNA (cDNA) generation Extracted RNA was quantified using the Qubit® RNA HS Assay Kit (ThermoFisher Scientific; Q32852) and Qubit® 4.0 fluorometer (excitation 600-645 nm and emission 665-720 nm) (ThermoFisher Scientific; Q33226), according to the manufacturer's instructions. Quantified RNA samples were subsequently treated with recombinant RNase-free DNase I (10,000U; Sigma Aldrich; 4716728001) and 50 mM MgCl 2 solution (Bioline; BIO-37026) to remove any trace DNA. Treated RNA was diluted to achieve 100 ng/50 µL for reverse transcription into cDNA using the High Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific; 4368814), according to the manufacturer's instructions. 50 µL of reverse transcription mastermix was added to diluted RNA samples before thermal cycling on a StepOnePlus PCR system™ for cDNA generation. The cycling conditions were holding at 25°C for 10 min, 37°C for 120 min, followed by 85°C for 5 min. cDNA was stored at -80°C until use.
Quantitative real-time PCR (qPCR) cDNA (2 ng/µL) was diluted to a final volume of 20 µL in TaqMan® 2x Fast Advanced Master Mix (ThermoFisher Scientific; 4444557) and TaqMan® gene expression probe solution (FAM-MGB dye-labelled, ThermoFisher Scientific) for KIF5A (Hs01007893_m1), KLC1 (Hs00194316_m1) RBFOX3 (Hs01370653_m1) and GAPDH (Hs02758991_g1). qPCR was performed on a StepOnePlus™ Real-Time PCR system with StepOne software v2.1 (ThermoFisher Scientific), on a FAST ramp speed, (Holding at 50°C for 2 min, 95°C for 2 min, cycling (x40) at 95°C for 1 s, followed by 60°C for 20 s). As the genes of interest are expressed predominantly neuronally, gene expression was calculated relative to that of a neuron-specific calibrator gene, encoding neuronal nuclear protein NeuN (RBFOX3), by the 2 -ΔΔct method. In addition, RBFOX3 levels were normalised to ubiquitous house-keeping gene GAPDH to assess any influence of PMD on gene expression. Table 2 ) and added overnight at 4°C. The primary antibodies used were: mouse anti-AβPP (ThermoFisher Scientific; 13-0200), mouse anti-GAPDH (Abcam; Ab9484); mouse anti-PHF-TAU (ThermoFisher Scientifc UK; MN1020), rabbit anti-KIF5A (Sigma-Aldrich Ltd; HPA004469), rabbit anti-KLC1 (Abcam; Ab174273) and rabbit anti-NeuN (Abcam; Ab177487). Bound primary antibody was detected by incubation with HRP-conjugated secondary antibodies for 1 h at room temperature (as detailed in Table 2 ). Protein expression was visualised using a chemiluminescence Clarity™ Western ECL Substrate (Biorad; 1705060). Antibodies displayed bands relative to their reported molecular weight, as described on manufacturer data sheets ( Figure 1 ).
Genotyping
Dot blot
Dot blot was performed using a Bio-Dot Microfiltration manifold (Biorad), according to the manufacturer's instructions. Nitrocellulose membrane was pre-soaked in 1x TBS and placed in the manifold, before addition of 100 µL of protein homogenate/well (diluted 1:200 with 1x TBS). After microfiltration for 90 min, the membrane was removed and placed in blocking antibody, before antibody incubation (Table 2) , as per the western blot protocol. Protein expression was visualised on a Biorad Universal III Bioplex imager, using a chemiluminescence Clarity™ Western ECL Substrate (Biorad). Image Lab™ 5.0 software (Biorad) was used for densitometric protein analysis. Integrated density values were expressed relative to the neuronal nuclear protein NeuN. In addition, NeuN protein levels were normalised to ubiquitous protein GAPDH to study any effect of PMD on protein expression.
Enzyme-linked immunosorbent assay (ELISA) AD frontal tissue (200 mg) was homogenised in TBS extraction buffer to obtain the soluble protein fraction and the protein pellet was homogenised in guanidine to obtain the insoluble fraction, as previously described 27, 32 . Sandwich ELISA was used Figure 1 . Antibody specificity. western blots performed using AD protein homogenates, derived from mid-frontal cortex. Predicted molecular weight of APP 110-135kDa. Antibody used for detection was mouse anti-APP (1:2000), ThermoFisher Scientific; 13-0200 (A). Predicted molecular weight of GAPDH 37kDa. Antibody used for detection was mouse anti-GAPDH (1:5000), Merck; MAB374 (B). Predicted molecular weight of KIF5A 107kDa and 117kDa. Antibody used for band detection was rabbit anti-KIF5A (1:1000), Sigma-Aldrich; HPA004469 (C). Predicted molecular weight of KLC1 60-70kDa. Antibody used for detection was rabbit anti-KLC1 (1:5000), Abcam; Ab174273 (D). Predicted molecular weight of NeuN 48kDa. Antibody used for detection was rabbit anti-NeuN (1:5000), Abcam; Ab177487 (E). Predicted molecular weight of paired-helical filament tau 45-65kDa. Antibody used for detection were mouse anti-PHF-Tau (1:500), ThermoFisher Scientific; MN1020 (F). APP: amyloid precursor protein; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; kDa: kilodaltons; KIF: kinesin superfamily motor protein; KLC1: kinesin light chain-1; MW: molecular weight; PHF: paired helical filament; NeuN: neuronal nuclear protein. to measure total Aβ in the fractions, with mouse monoclonal anti-Aβ (4G8 clone) (Biolegend; 800712; RRID: AB_2734548), for the capture step and biotinylated anti-human Aβ monoclonal antibody (10H3 clone) (ThermoFisher Scientific; MN1150B; RRID: AB_223641), for the detection step, as previously described 33 .
Immunoperoxidase staining of paraffin sections 7 µm sections from frontal cortex were dewaxed, hydrated, and immersed in 3% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase activity. Sections were subsequently rinsed in running tap water and pre-treated with sodium citrate buffer in the microwave (0.01 M, pH 6.0, 5 min) to unmask antigenic sites, then rinsed in PBS. Immunostaining was performed using VECTASTAIN® Universal Elite® ABC Kit (Vector Laboratories; PK-6200). Non-specific binding was blocked using horse serum for 30 min at room temperature, before incubation overnight at 4°C with anti-mouse monoclonal PHF-tau (1:2000) (ThermoFisher Scientific; MN1020; RRID: AB_223647), diluted in PBS. Sections were rinsed in PBS and incubated for 20 min with VECTASTAIN® biotinylated universal secondary antibody, followed by 20 min with VECTASTAIN® Elite® ABC complex (both Vector Laboratories; PK-6200), before a final 7 min with 3,3'-diaminobenzidine (DAB) (Vector Laboratories; SK4100). Sections were washed in water, immersed in copper sulphate DAB enhancer for 4 min (0.16 M Copper (II) sulphate 5-hydrate/0.12 M sodium chloride) and counterstained with Gills haematoxylin II (Sigma-Aldrich Ltd; GHS216) for 15 s. Sections were subsequently dehydrated, cleared and mounted in Clearium® (Leica Biosystems; 3801100). Controls in each run included sections incubated overnight in PBS instead of the primary antibody.
Immunohistochemical analysis
The percentage field fraction immunopositive for PHF-tau (insoluble tau load) was assessed in the cortex of frontal sections from AD and controls by computer-assisted image analysis using Histometrix software (Kinetic Imaging, Nottingham, UK) driving a Leica DM microscope with a motorised stage, as previously described 34, 35 . The area to be analysed was selected at low-magnification (x2.5) and the threshold for PHF-tau labelling density calibrated at high magnification (x20). The software was programmed to measure tau load in 30 random regions (x20 objective fields) within the selected area and determine the cumulative area fraction with a density exceeding the threshold value.
Statistical analysis
Univariate mRNA and protein analysis were performed using GraphPad Prism 5™ (GraphPad Software Inc.; San Diego, USA). Data normality was tested using the Shapiro-Wilk test. One-way ANOVA with post-hoc Bonferroni, or Kruskal-Wallis with post-hoc Dunns test, as appropriate, was used to analyse differences in mRNA and protein expression according to Braak stages and SNP genotype. Parametric Pearson's or non-parametric Spearman's correlation was used to assess any relationship between proteins. A multiple regression model (STATA v12; StataCorp LLC; Texas, USA) was used to analyse mRNA expression in relation to Braak stage pathology, patient age of death and tissue post-mortem delay. Where necessary, data were transformed to normality before regression analysis. For all tests, values of p < 0.05 were considered statistically significant.
Results
Cohort variables
With exclusion criteria, the study cohort comprised 47 AD cases and 39 controls, as detailed in Table 1 . The age of AD cases ranged from 54-98 y (mean 81, SD 9). Control cases ranged from 43-95 y (mean 80, SD 11). There were more females (n = 29) than males (n = 18) in the AD group, and fewer females (n = 15) than males (n = 24) in the controls. The PMD did not differ significantly between AD (37 h, SD 19) and controls (34 y, SD 20; two-tailed Mann-Whitney p = 0.34). There was no influence of PMD on RBFOX3 (NeuN) mRNA (normalised to GAPDH; n =70, Spearman r = -0.09, p = 0.47) or protein level (normalised to GAPDH; n = 79, Spearman r = -0.02, p = 0.87).
Significant increase in kinesin gene expression linked to AD pathology Expression of kinesin relative to RBFOX3 mRNA was measured by qPCR and analysed in relation to Braak tangle stage. KIF5A mRNA was significantly elevated at Braak stages III-IV (p < 0.01) and V-VI (p < 0.001), compared to stages I-II, (Figure 2A ). KLC1 mRNA was significantly elevated in late Braak stage disease (V-VI, p < 0.001) compared to stages I-II ( Figure 2B ). In a previous study we found an association between PMD and the level of KIF5A relative to RBFOX3 (NeuN) mRNA 27 but in the present cohort we found no effect of either patient age at death or PMD on expression of KIF5A or KLC1 relative to RBFOX3 (Table 3) .
Single nucleotide polymorphisms within the KIF5A gene locus influence KIF5A mRNA expression We previously showed that KIF5A protein level was reduced in post-mortem brain tissue from MS patients homozygous for SNPs within the KIF5A gene locus which have been linked to MS susceptibility 26 . We explored this in AD brain tissue using pre-designed TaqMan® SNP assays for rs12368653 and rs4646536, the latter in linkage disequilibrium (r 2 = 1) with rs703842, making it suitable as a proxy 36, 37 . The accuracy of the SNP was verified using 18 MS positive control genotypes from our previous studies 26 .
KIF5A mRNA expression was significantly lower in AD patients homozygous for the rs12368653 SNP (AA) than in AD patients with no copies (GG) (p<0.05; Figure 3A) . Similarly, AD patients homozygous for the rs4646536 SNP (AA) (proxy for rs703842), had significantly lower KIF5A mRNA than did heterozygous patients (AG) (p<0.05; Figure 3B ). There was no significant difference in KLC1 mRNA expression in AD patients stratified according to KIF5A SNPs (rs12368653 and rs4646536; Figure 3C and 3D). We subsequently investigated whether SNPs in the KLC1 gene that were previously linked to AD susceptibility 23,24 influence kinesin mRNA expression. There was no significant difference in KLC1 mRNA between AD patients heterozygous for the rs8702 SNP (GC) and those with no copies (GG; Figure 4A ). Similarly, there was no significant difference in KLC1 mRNA between AD patients heterozygous for the rs8007903 SNP (AG) and those with no copies (AA; Figure 4B ). Due to low cases numbers (n=2), homozygous expression could not be analysed. There was no significant effect of KLC1 SNPs on KIF5A mRNA expression ( Figure 4C and 4D ).
Kinesin protein level does not vary significantly with AD pathology Kinesin protein expression was measured by dot blot. In keeping with previous studies 27 , KIF5A expression did not differ significantly between Braak stages 0-II, III-IV and V-VI ( Figure 5A ). In addition, there was no significant variation in KLC1 protein level with Braak stage ( Figure 5B ). As expected, the levels of KIF5A and KLC1 protein were positively correlated (p < 0.001, Figure 5C ). There was no influence of SNPs within the KIF5A gene locus (rs12368653 and rs4646536) on KIF5A ( Figure 6A and 6B) or KLC1 protein level ( Figure 6C and 6D) .
Kinesin levels inversely correlate with amyloid precursor protein in AD As in previous studies 27, 38 , APP level did not differ significantly between AD and control cases ( Figure 7A ). APP levels correlated inversely with both KIF5A and KLC1 protein in AD (p < 0.05; Figure 7B and 7C). Neither KIF5A or KLC1 correlated with the level of soluble or insoluble Aβ or with the ratio of soluble: insoluble Aβ (Table 3) , although a trend was seen for lower levels of soluble Aβ to be associated with higher levels of KIF5A (p=0.10; Table 3), as in our previous study 27 . As expected, soluble and insoluble Aβ levels were significantly higher in AD than controls ( Figure 8A and 8B).
KIF5A protein level correlates inversely with soluble paired helical filament tau
The level of hyperphosphorylated tau in the soluble protein fraction was significantly increased in AD compared with control cases ( Figure 9A ). The level correlated inversely with KIF5A protein level (p<0.05) but not with KLC1 protein in AD ( Figure 9B and 9C) . Western blot analysis showed additional bands above the predicted molecular weight of tau (45-65kDa), most likely attributed to phosphorylated epitopes 39 . In addition to immunoblotting, hyperphosphorylated tau levels were measured by quantitative immunohistochemistry and showed a significant positive correlation with hyperphosphorylated tau protein levels measured by dot blot (p<0.001; Figure 9D ). There was no correlation between KIF5A or KLC1 protein level and insoluble tau load (Table 4) .
Discussion
Previous studies in mouse models implicated defective functioning of KLC1 in disruption of axonal transport in AD 21, 40 . In the current study of human tissue from AD and control cases, we have found KLC1 and KIF5A gene expression to be elevated in AD and associated with Braak tangle stage. We have also demonstrated significant inverse correlations between kinesin levels and AD-associated proteins, APP and PHF-tau. We did not find any association between KLC1 gene expression and KLC1 SNPs reportedly linked to AD.
Four KLC genes are expressed in mammals but those involved in axonal transport are KLC1 and KLC2. KLC1 is neuronally enriched whereas KLC2 is ubiquitously expressed 41 . A coiledcoil region at the amino terminus of the KLCs binds to the stalk domain (close to the carboxyl terminus) of conventional kinesins (KIF5A, KIF5B and KIF5C) and acts as an adaptor complex for indirect binding and transport of cellular cargoes, such as APP 29 .
Expression of both KLC1 and KIF5A mRNA was positively associated with Braak tangle stage, a widely used marker of AD progression, defined by the distribution of hyperphosphorylated tau pathology distribution within the brain 42 . KIF5A mRNA was upregulated at relatively early stages of disease (Braak stages III-IV), in keeping with previously reported evidence of early-stage axonal abnormalities in AD and other neurodegenerative diseases 13,21,40 . Upregulation of both KIF5A and KLC1 mRNA may be a compensatory response to other pathological processes that interfere with axonal transport of protein cargoes to the synapse. Elevated kinesin gene expression in human tissue has been demonstrated in several neurodegenerative diseases 15,28,43 .
Genome-wide association studies (GWAS) have shown linkage of multiple genes to AD susceptibility, including some genes encoding proteins with roles in axonal transport and cytoskeletal function (NME8, CELF1, and CASS4) 3 . However, GWAS are unable to detect rare variants linked to susceptibility. Such variants include SNPs within the KLC1 gene, which have been linked to early AD pathogenesis. In particular, rs8702 was reported to predict conversion from mild cognitive impairment to AD and was associated with levels of hyperphosphorylated tau in patient cerebrospinal fluid 16 . It is hypothesised that this SNP could influence the splicing of c-terminal epitopes in KLC1 gene transcripts 16 , which could affect cargo binding affinity, axonal transport and synaptic function, causing structural instability and eventual neuronal degeneration. The effective 'strain' on the neuron caused by transport defects is likely to be exacerbated by a reduction in mitochondrial ATP supply associated with aging 44 . We found no effect on KLC1 expression of heterozygosity of the rs8702 'C' risk allele or rs8007903 'G' allele but did not have sufficient cases to analyse the influence of homozygosity of the SNPs. Larger genetic studies found no effect of rs8702 on AD susceptibility but a significant interaction with APOE ε4 carrier status in patients 16 . The continuing uncertainty as to the influence of KLC1 polymorphisms on the risk of AD highlights the difficulties of linkage studies for rare variants, which are often hampered by small sample size, locus heterogeneity and false-positive results
.
We previously found a significant reduction in KIF5A expression in MS tissue in homozygous carriers of the rs703842 'A' allele and rs12368653 'A' allele 25, 26 , which are linked to MS susceptibility 36, 45 . GWAS have identified susceptibility variants common to MS and sporadic AD, including major histocompatibility complex gene HLA-DRB1
3 . In the present study, we found a significant reduction in KIF5A mRNA expression in AD patients homozygous for the rs4646536 'A' allele (proxy for rs703842 37 ) and rs12368653 'A' allele, compared to heterozygotes and non-carriers. Variability within the KIF5A gene locus may be a common denominator across a spectrum of neurodegenerative conditions. KIF5A mutations are linked to several axonopathies, including hereditary spastic paraplegia and . Assay sensitivity may also be relevant and some changes in KLC1 metabolism missed due to the complex carboxyterminal splicing, which results in multiple variants 53 with varied affinities for the antibody used in the present study. Evidence from one study suggests that alternative splicing of KLC-1 can create a functional variant (E) that causes Aβ accumulation 54 . Co-immunoprecipitation studies have demonstrated at least 6 variants of conventional kinesin (KIF-5A/5B/5C with KLC1 or KLC2); however, with alternative splicing of KLC1 the number is likely to be much higher 30 . The multiplicity of splice variants is attributed to the large variety of membrane cargoes that require transportation to distinct neuronal compartments 1 . For future studies, it would be interesting to study the expression pattern of additional KIF5 (5B and 5C) and KLC (KLC-2) family members, for expression profiling in different cortical regions of AD brain.
Irrespective of overall kinesin protein levels, evidence points to disruption of convention kinesin transport in AD, through phosphorylation-mediated dissociation of KIF from both its cargo and from the microtubule 55 . Studies of transgenic mouse models have suggested that Aβ can be transported within neurites and have shown a correlation between axonal swellings positive for intracellular Aβ and the location of extracellular insoluble Aβ deposits 22 . In addition, studies in the squid giant axon have shown that Aβ oligomers can inhibit axonal transport through activation of casein kinase 2, which phosphorylates KLC1, reducing its cargo binding affinity 56, 57 . We found no significant correlation between KIF5A or KLC1 and insoluble Aβ levels, despite a trend towards lower soluble Aβ with higher KIF5A, as in our previous study 27 . We found significant inverse correlations between APP expression and both KIF5A and KLC-1. From this, we hypothesise that reduced APP transport by kinesin prolongs exposure of APP to secretases and increases amyloidogenic cleavage, which creates a negative feedback loop for Aβ-mediated impaired axonal transport 58 , although further experiments are required to validate this hypothesis.
There was a significant negative correlation between KIF5A and soluble hyperphosphorylated tau levels, but not with the insoluble tau load as determined immunohistochemically. Pathogenic forms of tau enhance glycogen synthase kinase 3β (GSK3β) activity by increasing exposure of the phosphatase-activating domain in the amino terminus of tau, which increases protein-phosphatase 1-dependent activation of GSK3β 59 . Elevated GSK3β causes KLC1 phosphorylation and results in protein cargo dissociation 40 .
Kinesin phosphorylation is emerging as a potent modulator of axonal transport in neurodegenerative diseases and this pathway presents a potential modifiable target for treatment 1, 60 . Based on the previous phosphorylation studies mentioned and our human tissue findings, it seems that the relationship between kinesin protein expression and AD pathology would be better untangled using a transgenic mouse model of AD. Recent studies have highlighted the advantages of using in vivo time-lapse imaging in a rodent model for monitoring changes in axonal transport 61 . Studies in ALS mouse models using in vivo time-lapse have indicated axonal transport disturbances represent an early change in disease pathology and are not merely a 'by-product' of insidious neurodegeneration 62 . This in vivo imaging technology could be employed to explore early changes in the frequency and speed of KIF5A/KLC-1 mediated vesicle transport in familial (APP/presenilin 1 mutation) AD mouse models. The technology would also allow for a more in-depth analysis of any potential transport redundancy between KIF5A and KLC-1 using gene silencing or interference. In addition, in vivo imaging could be used to explore the role of phosphorylation-mediated kinesin cargo uncoupling which has been highlighted in other AD mouse studies and would allow for testing of various kinase inhibitors on restoring axonal transport rates.
Overall, we show that both KIF5A and KLC-1 mRNA are upregulated in AD tissue and that genetic polymorphisms within the KIF5A gene locus influence KIF5A gene expression. The findings do not indicate that upregulation of KIF5A is a result of functional redundancy between KIF5A and KLC1 in protein transport, or that the expression of KLC1 in cerebral cortex is influenced by KLC1 polymorphisms, which have been linked to AD susceptibility. In future studies it would be useful to perform full expression profiling of KIF5 and KLC members in post-mortem tissue from multiple cortical regions. In addition, further studies analysing the effect of kinesin upregulation (and highlighted KIF genetic polymorphisms), on axonal transport mechanisms, through both in vitro axonal cultures and in vivo AD rodent models, using time-lapse imaging would be of significant interest.
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The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. A substantial literature has implicated axonal transport deficits as a component of pathogenesis in AD and other adult-onset neurodegenerative diseases. Some evidence has been published from GWAS studies suggesting that altered expression of molecular motor proteins or genetic polymorphisms in KLC1 may be risk factors for AD, but relatively little has been done to document specific changes in patient materials. In this study, the investigators have evaluated expression of two genes that are candidates for a role in AD, taking advantage of access to midfrontal cortex tissue from 47 AD and 39 control human brains. The set of brains are relatively well matched in terms of mean age and postmortem delay for control and AD. Based on age at the time of death, the AD patients are likely to be mostly sporadic cases with 5-10% familial cases, which is consistent with the population levels. Both males and females are considered together. The authors do not stratify by familial vs sporadic or male vs female.
The focus here is on expression of KIF5A and KLC1, both of which have been reported to have polymorphisms associated with neurological diseases. In addition, the authors cite literature claiming that KIF5A complexed to KLC1 is responsible for transport of vesicles containing APP as well as band g-secretases. Unfortunately, those studies have never been replicated despite concerted effort by multiple groups (see for example O. Lazarov, et al. (2007) . Impairments in fast axonal transport and motor ). A neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1 . more rigorous study of APP transport showed that the primary motor was KIF5C and that neither bor g-secretases were co-transported (A. Szodorai, et al. (2009) 
. APP anterograde transport requires
). Nevertheless, evidence from this group Rab3A GTPase activity for assembly of the transport vesicle and others that show increased expression of KIF5A in AD and data from GWAS and transcriptomic studies showing association of polymorphisms and splice variants of KLC1 with AD justify analysis of expression for these two genes.
The data showed an increase in mRNA for KIF5A confirming previous studies and indicate that KLC1 mRNA levels also increase. Data is also presented on changes in expression related to a polymorphism in KIF5A previously associated with reduced KIF5A and susceptibility to multiple sclerosis. While a small difference was seen with the AA genotype that was significant when analyzed by ANOVA, the effects were modest at best and were not compelling. No differences were detected with polymorphisms in KLC1. Similarly, protein levels of KIF5A and KLC1 were not different with either polymorphisms or Braak stage. The authors then looked at levels of Aband PHF-tau, finding that, of course, they both increase in the AD patients. Not surprisingly, the KIF5A levels correlated inversely with increased which is to be expected since KIF5A levels don't change while the Aband PHF-tau increase. Given the scatter of the data, it is not clear that these are meaningful correlations. In the present manuscript Kelly Hares and co-workers aimed (as stated by the authors) "to determine whether KLC1 levels are altered in AD, the relationship between the levels of KLC1 and KIF5A, and whether expression of KLC1 in the cerebral cortex is influenced by KLC1 polymorphisms, which have been linked to AD susceptibility." No significant effects of KLC1 SNPs on KIF5A mRNA expression. Discussion Section:
The authors discuss that they found KLC1 and KIF5A mRNA levels to be elevated in AD associated with Braak tangle stages. Hares and coworkers found an inverse correlation between kinesin levels and AD-associated proteins. It is worth mentioning that the inverse correlation is observed only with APP but not with soluble or insoluble Aβ, and that they observed a trend with lower levels of soluble Aβ to be associated with higher levels of KIF5A.
The authors claim that the elevated levels of KIF5A mRNA and KLC1 mRNA in AD brain samples may be a compensatory response to other pathological processes that interfere with axonal transport of protein cargoes to the synapse. The authors found lower KIF5A mRNA levels in SNPs with susceptibility for MS but no changes in protein levels; and lastly the authors found no changes in KLC1 mRNA in the same samples. Based on all their findings the authors highlight the importance of KIF5A in maintaining axonal transport and raise the possibility that patients with higher "reserve levels" of KIF5A are less susceptible to axonal transport disruption and pathology. Similarly, the authors propose based on their results that genetic polymorphisms within KIF5A gene locus could represent a common neurodegenerative pathway across a spectrum of neurological conditions.
Personal Report:
The experimental evidences provided by Kelly Hares and co-workers, although interesting, are very preliminary and highly speculative. The authors found increased levels of mRNA for KIF5A and KLC1 in AD brain samples but did not observe any effects at protein levels. Interestingly, unlike their previous report, results obtained with a new cohort of AD and control brain samples showed that KIF5A protein levels did not changed between Braak stages 0-II, III-IV or V-VI. Similarly Hares and co-workes did not find any changes in KLC1 or KIF5A protein levels associated to different SNPs within the KIF5A gene locus (rs12368653 and rs4646536) associated with increased susceptibility to AD. Based on these results, this reviewer does not see why the authors emphatically suggest that KIF5A is highly important in maintaining axonal transport, without even analyzing other KIF5s, in particular the neuronal specific KIF5C, as well as KLC2. Recent reports have determined that functional mutations in KIF5A are associated to different progressive neuropathies, as stated by Hares and co-workers in their manuscript, highlighting the critical role that plays KIF5A in maintaining the transport of important axonal cargoes that other wise result in pathology. Similarly, it is not evident for this reviewer why the presence of more mRNA for KIF5A (termed"reserve levels"by the authors), which does not result in an increase in KIF5A protein level, will make AD patients less susceptible to axonal transport disruption and pathology. It would be very informative if the authors could propose any particular molecular mechanism to explain such categorical statement. In summary, although preliminary in my opinion, the results obtained by Hares et al. are interesting and promising, however the authors extend too far their discoveries without proposing any particular hypothesis driven mechanism. We thank the reviewer for their comments. On reflection, we agree the conclusions are too presumptuous and not fully supported by the findings. In light of this, we have amended the manuscript to be less speculative (abstract page 2, discussion page 17) and clarified the hypothesis proposed. We are pleased the reviewer felt the results are interesting and promising and we feel that the results are of interest to others, irrespective of the fact that we did not show redundancy between KIF5A and KLC-1 as originally hypothesised. We did see significant changes in KIF5A and KLC-1 gene expression and in particular, a rise in KIF5A gene expression at early Braak stages (III-IV). We also saw genotype influenced KIF5A gene expression in AD patients homozygous for a SNP within the KIF5A gene locus that has previously been linked to MS susceptibility. These findings are novel but we agree that they are preliminary and warrant future investigation or in vitro in vivo for a more comprehensive study of the mechanisms and downstream effects of dysregulated kinesin expression. We have also added this to the discussion (page 17).
We agree with the reviewer that in the context of a larger study, it would be beneficial to analyse the expression of other KIF5 subtypes and KLC2, to strengthen the case for KIF5A as being particularly important in maintaining transport. This point has now been included in the discussion (page 15). We were interested in analysing the relationship between neuronally enriched KIF5A and KLC-1, as they complex together for anterograde axonal transport of several protein cargoes implicated in AD pathology.
We studied neuronally enriched KLC-1 due to genetic polymorphisms within the gene being linked Although we appreciate a thorough analysis of all KIF5 members would be interesting for comparison purposes, a large body of evidence implicates KIF5A in human axonopathies. It is only mutations within the KIF5A motor protein that have been linked to diseases such as CMT-2A, SPG10 and ALS (Crimella, et al. 2012 and Brenner, et al. 2008 ). Moreover, only SNPs within the KIF5A gene locus (not the other KIF5 members) have been linked to MS susceptibility and our previous studies have highlighted changes in neuronally enriched KIF5A within MS human tissue (Hares, et al. 2016) . We have an interest in whether SNPs within the KIF5A gene locus are associated with neurodegenerative processes across a range of neurological disorders. Mouse studies have also implicated KIF5A with axonal transport defects but not 5B or 5C (Xia, et al. 2003 ) and more recently a FAD mouse model has shown reduced levels of KIF5A but not KIF5C (Wang, et al. 2019) . In addition, studies in zebrafish have found KIF5A is essential for mitochondrial localisation and transport could not be compensated for by other KIF5 members (Campbell, et al. 2014) . Therefore, based on both previous human and animal findings and the unique complexing of KIF5A and KLC-1 for cargo transport, we focused on these two members for the purpose of this study.
We hypothesise that higher levels of KIF5A would mean axonal transport is sustained for longer under stress or disease conditions and that axons would be less likely to form large protein accumulations which can cause Wallerian degeneration and cellular toxicity (we have removed the term 'reserve levels' from the discussion). Others support this hypothesis and have suggested reduced transport of APP by kinesin prolongs exposure of APP to secretases, increases amyloidogenic cleavage and results in Aβ accumulation in transport vesicles that undergo exocytosis. In addition, reduced kinesin transport of other cargoes that regulate APP proteolysis (Apolipoprotein E receptor 2; ApoER2, calsyntenin and JNK-associated leucine zipper protein; JLP) can promote Aβ retention within the secretory pathway (Gan, et al 2014). We have also found significant inverse correlations between KIF5A and APP/dephosphorylated neurofilament in previous studies, which are associated with axonal transection in MS (Hares, et al. 2016 ).
It is plausible that upregulated KIF5A mRNA expression in AD does not result in higher protein levels due to modification of kinesin metabolism in AD via Aβ, which could be part of a negative feedback loop between APP transport and processing (Gan, et al. 2014 ). Recent studies in vitro and using FAD mouse models have shown Aβ reduces KIF5A expression and disrupts KIF5A-mediated mitochondrial transport, which can be rescued by restoration or overexpression of KIF5A (Wang, et al. 2019 ). This is mentioned in the discussion and has been expanded (Page 15).
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